Cite
HARVARD Citation
Terauchi, Y. et al. (2019). Long‐term safety and efficacy of the sodium–glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week open‐label, multicenter, post‐marketing clinical study. Journal of diabetes investigation. 10 (6), pp. 1518-1526. [Online].